Syndax Q2: Analysts Press on Revuforj, Niktimvo Patient Starts

Syndax Pharmaceuticals held its second-quarter earnings call on Aug. 4 after the close. CEO Michael Metzger, CFO Keith Goldan, Chief Commercial Officer Steve Closter, and Chief Medical Officer Nick Botwood presented results and fielded questions from analysts at Guggenheim, Jefferies, TD Cowen, Stifel, Barclays, Mizuho, H.C. Wainwright, and B. Riley.

Closter updated the commercial trajectory for Revuforj (revumenib), the menin inhibitor approved for menin-mutant acute leukemia, and Niktimvo (axatilimab), the treatment for chronic graft-versus-host disease. Both drugs launched within the past year. Closter said the company is focused on building prescriber awareness and securing payer coverage. He did not disclose specific patient-start numbers on the call.

Goldan reviewed the quarterly financials without releasing specific revenue, expense, or cash figures in the prepared remarks. He said the balance sheet supports the company's commercial and pipeline plans through key milestones. Syndax ended the quarter with what management called sufficient runway to fund operations into 2028, according to the slide deck posted on the investor page.

Analysts pressed on the pace of patient starts for Niktimvo and the competitive positioning of Revuforj. The menin inhibitor field includes several other developers, and analysts asked how Revuforj's label differentiates it. Botwood noted that the drug's Phase 3 trials in additional indications are enrolling and that data readouts remain on schedule. He did not give a specific timeline.

The company reiterated its full-year guidance for both products. That implies management sees no need to revise expectations based on the first half of 2026.

Beyond the commercial launches, the pipeline focus is on expanding revumenib into other genetically defined leukemias. The Phase 3 program covers multiple cohorts. Botwood said enrollment is progressing, though he declined to project a data date.

Syndax shares trade under the ticker SNDX. The stock has moved in line with the broader market this year, with the next major catalyst likely being Phase 3 data from the revumenib program.

The call wrapped with Metzger thanking the team and reiterating the company's commitment to bringing both drugs to more patients. The next quarterly update is expected in early November.